Yahoo Web Search

  1. Edited Transcript of IMMU earnings conference call or presentation 30-Oct-19 9:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceOct 31 22:53 PM

    Given that we've already completed the commercial launch preparation once before, we believe that we're well...registration path forward for SG and this important indication with the FDA. The ...

  2. Edited Transcript of NERV earnings conference call or presentation 4-Nov-19 1:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 06 3:06 AM

    Our last clinical stage product, seltorexant, is under co-development with Janssen Pharmaceutica. During 2019, we completed and announced top line results from 3 Phase IIb trials ...

  3. Edited Transcript of TCON earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 09 22:43 PM

    Charles P. Theuer, TRACON Pharmaceuticals, Inc. - CEO, President & Director [2] Good afternoon and thank you for joining TRACON's Third Quarter 2019 Financial Results and Business Update Conference Call.

  4. Edited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 13 4:11 AM

    As you know, we have a preclinical collaboration in place with Janssen for NKTR-255, and they are currently evaluating the agent in combination with several different therapies in their ...

  5. Edited Transcript of TBPH earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 09 15:43 PM

    In September we also announced 5202, our gut-selective irreversible JAK3 inhibitor progressed into clinical development. Both Theravance and our partner Janssen believe 5202 provides ...

  6. Edited Transcript of GEN.CO earnings conference call or presentation 6-Nov-19 5:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 07 7:53 AM

    We anticipate key additional approvals in 2020 following Janssen's submission of applications to both U.S. and European regulatory authorities for the subcutaneous formulation of daratumumab ...